Evaluation of 11C-colchicine for PET imaging of multiple drug resistance

Journal of Nuclear Medicine

Volumn 41, Issue 3, 2000, Pages 493-501

  Levchenko, Andre ^b   Mehta, Bipim M ^a   Lee, Jong Bin ^b   Humm, John L ^b   Augensen, Finn ^b   Squire, Olivia ^b   Kothari, Paresh J ^b   Finn, Ron D ^b   Leonard, Edward F ^b   Larson, Steven M ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

Colchicine; Mathematic model; Multiple drug resistance; PET

Indexed keywords

CARBON 11; COLCHICINE; GLYCOPROTEIN P; PACLITAXEL; CARBON; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MATHEMATICAL MODEL; MOUSE; MULTIDRUG RESISTANCE; NEUROBLASTOMA CELL; NONHUMAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR CELL LINE; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FLOW CYTOMETRY; METABOLISM; NEUROBLASTOMA; NUDE RAT; THEORETICAL MODEL; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; CARBON RADIOISOTOPES; COLCHICINE; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; MODELS, THEORETICAL; NEUROBLASTOMA; P-GLYCOPROTEIN; RATS; RATS, NUDE; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033622160     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Beck WT. Mechanisms of multidrug resistance in human tumor cells: the roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev. 1990;17(suppl):11-20.
2. Bellamy T. P-glycoproteins and multidrug resistance. Ann Rev Pharmacol Toxicol. 1996;36:161-183.
3. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev. 1996;6:610-617.
4. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract. 1996;192:768-780.
5. Suto R, Abe Y, Nakamura M, et al, Multidrug resistance mediated by overexpression of P-glycoprotein in human osteosarcoma in vivo. Int J Oncol. 1998;12:287-291.
6. Crankshaw CL, Marmion M, Luker GD, et al. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P glycoprotein. J Nucl Med. 1998;39:77-86.
7. Piwnica-Worms D, Rao V, Kronauge J, Croop J. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry. 1993;34:12210-12220.
8. 99mTc-sestamibi scan in untreated breast cancer patients. Eur J Nucl Med. 1997;24:150-159.
9. 99mTc-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med. 1997;38:1348-1345.
10. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium-99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 1998;16:1677-1683.
11. Hofmockel G, Bassukas ID, Wittmann A, Dammrich J. Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer? Br J Urol. 1997;80:11-17.
12. 99mTc-tetrofosmin in breast cancer. Q J Nucl Med. 1997;41:239-250.
13. Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol. 1994;12: 2453-2459.
14. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia. 1995;9:1661-1666.
15. Haber M, Bordow SB, Haber PS, Marshall GM, Stewart BW, Norris MD. The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer. 1997;33:2031-2036.
16. Pogliani EM, Belotti D, Rivolta GF, Maffe PF, Corneo G. Anthracycline drugs and MDR expression in human leukemia. Cytotechnology. 1996;19:229-235.
17. de Silva M, Kantharidis P, Wall DM, et al. Inheritance of chromosome 7 associated with a drug-resistant phenotype in somatic cell hybrids. Br J Cancer. 1996;73:169-174.
18. Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, Ford RC. Structure of the multidrug resistance P-glycoprotein. Semin Cancer Biol. 1997;8:135-142.
19. Rosenberg MF, Callaghan R, Ford RC, Higgins CF. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem. 1997;272:10685-10694.
20. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010-3020.
21. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA. 1990;87:7160-7164.
22. Herzog CE, Trepel JB, Mickley LA, Bates SE, Fojo AT. Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. J Natl Cancer Inst. 1992;84:711-716.
23. Kostakoglu L, Elahi N, Kiratli P, et al. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 1997;38:1003-1008.
24. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993;53:977-984.
25. 99mTc-sestamibi in oncology. Tumori. 1996;82:12-21.
26. Kostakoglu L, Kiratli P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med. 1998;39:228-234.
27. Hendrikse NH, De Vries EGE, Schinke AH, et al. P-glycoprotein mediated pharmacokinetics of radiopharmaceuticals analyzed by positron emission tomography in vivo [abstract]. Proc Am Assoc Cancer Res. 1997;39:385.
28. 11C]-daunorubicin and positron emission tomography [abstract]. Proc Am Assoc Cancer Res. 1998;39:71.
29. Roepe PD, Wei LY, Hoffman MM, Fritz F. Altered drug translocation mediated by the MDR protein: direct, indirect, or both? J Bioenerg Biomembr. 1996;28:541-555.
30. Wadkins RM, Roepe PD. Biophysical aspects of P-glycoprotein-mediated multidrug resistance. Int Rev Cytol. 1997;171:121-165.
31. Mehta BM, Levchenko A, Rosa E, et al. Evaluation of carbon-14-colchicine biodistribution with whole-body quantitative autoradiography in colchicine-sensitive and -resistant xenografts. J Nucl Med. 1996;37:312-314.
32. Mehta BM, Rosa E, Biedler JL, Larson SM. In vivo uptake of carbon-14-colchicine for identification of tumor multidrug resistance. J Nucl Med. 1994;35: 1179-1184.
33. 3H-colchicine. J Nucl Med. 1992;33:1373-1377, 1619.
34. Ferrand VL, Montero JF, Chauvet MM, Hirn MH, Bourdeaux MJ. Quantitative determination of the MDR-related P-glycoprotein, Pgp 170, by a rapid flow cytometric technique. Cytometry. 1996;23:120-125.
35. Fonti R, Levchenko A, Mehta BM, Zhang J, Tsuruo T, Larson SM. Measurement of P-glycoprotein expression in human neuroblastoma xenografts using in vitro quantitative autoradiography. Nucl Med Biol. 1999;26:35-41.
36. Kothari PJ, Finn RD, Larson SM. Syntheses of colchicine and isocolchicine labelled with carbon-11 and carbon-13. J Label Comp Radiopharm. 1995;36:521-528.
37. Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. Pharmacotherapy, 1991;11:196-211.
38. Famaey JP. Colchicine in therapy: state of the art and new perspectives for an old drug. Clin Exp Rheumatol. 1988;6:305-317.